Modified influenza virus for monitoring and improving vaccine efficiency
AssigneeSt. Jude Children's Research Hospital
InventorsErich Hoffmann, Aleksandr S. Lipatov, Richard J. Webby, Elena A. Govorkova, Robert G. Webster
Life of this patent
Estimating the term…
Abstract
The immunogenicity of the influenza virus hemagglutinin (HA) molecule may be increased by substitutions of amino acids in the HA sequence. The substitution of specific HA residues, such as asparagine at position 223 of H5 HA, increase the sensitivity of the hemagglutinin inhibition (HI) assay by altering receptor specificity and/or antibody-antigen binding. HA molecules containing such substitutions will be useful in the development of diagnostic reference viruses and improved influenza vaccines.
Claims20
An immunogenic composition comprising
- (a) a recombinant influenza virus H5 hemagglutinin (HA) molecule, wherein said recombinant H5 HA molecule:
- (i) comprises one or more amino acid sequence changes as compared to a naturally occurring HA molecule that comprises an amino acid other than asparagine at an amino acid position corresponding to amino acid position 223 in H5 HA;
- (ii) comprises an asparagine at an amino acid position corresponding to amino acid position 223 in H5 HA;
- (iii) has an increased reactivity with antisera derived from an animal exposed to an H5 influenza virus or an H5 influenza vaccine as compared to said naturally occurring HA molecule;
- and
- (iv) is not A/HK/213/03 HA molecule, and
- (b) a carrier.
An immunogenic composition comprising
- (a) a recombinant influenza virus comprising a recombinant influenza virus H5 hemagglutinin (HA) molecule, wherein said recombinant H5 HA molecule:
- (i) comprises one or more amino acid sequence changes as compared to a naturally occurring HA molecule that comprises an amino acid other than asparagine at an amino acid position corresponding to amino acid position 223 in H5 HA;
- (ii) comprises an asparagine at an amino acid position corresponding to amino acid position 223 in H5 HA;
- (iii) has an increased reactivity with antisera derived from an animal exposed to an H5 influenza virus or an H5 influenza vaccine as compared to said naturally occurring HA molecule;
- and
- (iv) is not A/HK/213/03 HA molecule, and
- (b) a carrier.
Dependencies are inferred from the claim text.